Allelic variation in the canine Cox-2 promoter causes hypermethylation of the canine Cox-2 promoter in clinical cases of renal dysplasia
© Whiteley; licensee BioMed Central Ltd. 2014
Received: 2 November 2013
Accepted: 17 March 2014
Published: 3 April 2014
Novel allelic variants in the promoter of the canine cyclooxygenase-2 (Cox-2) gene are associated with renal dysplasia (RD). These variants consist of either deletions of putative SP1 transcription factor-binding sites or insertions of tandem repeats of SP1-binding sites located in the CpG island just upstream of the ATG translation initiation site. The canine Cox-2 gene was studied because Cox-2-deficient mice have renal abnormalities and a pathology that is strikingly similar to RD in dogs.
The allelic variants were associated with hypermethylation of the Cox-2 promoter only in clinical cases of RD. The wild-type allele was never methylated, even in clinical cases that were heterozygous for a mutant allele. In cases that were biopsy-negative, the promoter remained unmethylated, regardless of the genotype. Methylated DNA was found in DNA from various adult tissues of dogs with clinical RD.
The mechanism of action of the allelic variation in the canine Cox-2 promoter most likely involves variation in the extent of epigenetic downregulation of this gene. This epigenetic downregulation must have occurred early in development because methylated Cox-2 promoter DNA sequences are found in various adult tissues.
KeywordsPromoter methylation Epigenetics Renal dysplasia SP1 CpG island Cyclooxygenase-2
Renal dysplasia (RD) or improper development of the kidneys is a life-threatening disease that can result in end-stage renal failure. In all species, RD can be genetic or acquired. There has been intense speculation regarding the role of epigenetic modifications in kidney development ; however, to my knowledge this report is the first documented case involving allele-specific epigenetic changes associated with kidney disease.
Cyclooxygenase-2 (Cox-2) is generally considered to be a rate-limiting enzyme for prostaglandin synthesis in response to biological events such as injury, inflammation, and proliferation . Transcriptional regulation of Cox-2 is complex. In most tissues, Cox-2 requires activation by inflammatory or other stimuli and is regulated by numerous 5′ transcription factors in addition to post-transcriptional regulation through elements at the 3′ untranslated region of the gene . However, in the adult kidney and several other organs, Cox-2 is constitutively expressed in various cell types, and its expression increases under non-physiological conditions . Furthermore, Cox-2 also functions as a developmental gene, as evidenced by knockout and knockdown mouse models that show abnormal kidney development [5–7]. Cox-2 knockdown mice have a less severe phenotype than Cox-2 knockout strains. Furthermore, expression studies in developing rats show that Cox-2 has highly specific and tightly regulated gene expression.
In the developing rat Cox-2 protein and mRNA are not detected until mid-gestation, but Cox-2 expression is high from day 15 and increases up to day 20. In the fetus, Cox-2 expression is restricted to the skin, heart, cartilage, and kidney . A similar pattern of Cox-2 expression has been reported during mouse and human development [9, 10].
Cox-2-deficient mice have renal abnormalities and a pathology that is very similar to RD in dogs [5, 6]. DNA sequencing of the canine Cox-2 gene revealed allelic variants with insertions or deletions of SP1-binding sites just upstream of the ATG translation start site .
These allelic variants exist within a large CpG island in the Cox-2 promoter near the translation start site; this CpG island is approximately 450 nucleotides long (as predicted by MethPrimer) . Normally, the CpG island in the human Cox-2 promoter is unmethylated. However, hypermethylation of the human Cox-2 CpG island has been identified in some types of cancer [13, 14], in which the level of Cox-2 repression increased with higher levels of methylation.
The aim of this study was to determine whether these allelic variants cause hypermethylation of the CpG island in the canine Cox-2 promoter in clinical cases of RD. Such hypermethylation would provide a mechanism by which these alleles could decrease or silence COX-2 expression during a critical time of development and generate a phenotype that is similar to the mouse knockout [5, 6] and knockdown  models of RD.
DNA samples used in the study
DNA samples were obtained from cheek cells or preserved kidney tissue (preserved in RNALater (Qiagen Inc., Valencia, CA, USA) or as formalin-fixed and paraffin-embedded tissue sections). All of the samples were harvested in a previous study . For bisulfite conversion, the DNA from the cheek swabs was concentrated using a DNA Clean & Concentrator™ kit from Zymo Research Corp. (Irvine, CA, USA). The DNA from kidney tissue preserved in RNALater was extracted using a mini gDNA extraction kit (Zymo Research Corp.).
DNA samples were obtained from five dogs with clinical cases of moderate to severe RD (>35% fetal glomeruli on biopsy). In addition, there were three biopsy-negative samples and five samples from randomly chosen dogs with a homozygous wild-type Cox-2 genotype. A negative biopsy indicated that no fetal glomeruli were present in the kidney section examined.
Bisulfite conversion and methylation-specific PCR
The DNA was bisulfite modified using the EZ DNA Methylation-Lightning™ Kit (Zymo Research Corp.). Primers for methylation-specific PCR  and DNA sequencing were chosen using MethPrimer  as follows.
Methylated DNA-specific primer set:
M forward primer, 5′-TGTTTTTTTTAGCGTCGTAGTTTC-3′
M reverse primer, 5′-AAAAACCAAATACCCACCTACG-3′
Unmethylated DNA primer set:
Forward primer, 5′-TGTTTTTTTTAGTGTTGTAGTTTTGA-3′
Reverse primer, 5′-AAAAACCAAATACCCACCTACAC-3′
The PCR conditions were 95°C for 1 min, followed by 35 cycles of 95°C for 15 s, 52°C for 15 s, and 72°C for 10 s, using MyTaq hot-start polymerase (Bioline, Taunton, MA, USA).
To obtain sufficient DNA for sequencing of the methylated DNA, the methylation-specific PCR products were separated on a PCR-CheckIT gel (Elchrom Scientific AG, Cham, Switzerland) with 1× buffer as recommended by the manufacturer. Individual alleles were recovered from the gel using BandPick™ (Elchrom Scientific) and re-amplified with the primers described above for DNA sequencing. The DNA was re-amplified using MyTaq hot-start polymerase for 30 cycles. The fragments were sequenced by Macrogen Corp. (Rockville MD, USA).
The PCR products from methylation-specific PCR were separated on a Spreadex 300 gel (Elchrom Scientific) with 1× TAE as the running buffer. Xylene cyanol loading buffer was run to the bottom of the gel.
Genotypes and clinical information for dogs used in this study
Methylated DNA products
Source of DNA
Age at death from renal failure
Formalin preserved kidney tissue
English cocker spaniel
Allele1–allele 4 are the variants shown in Figure 1. +, Indicates that biopsy data showed moderate to severe renal dysplasia (>35% fetal glomeruli); –, indicates that no fetal glomeruli were found in the biopsy; n/a, not available; wt, wild-type.
The first evidence that Cox-2 acts a critical gene in development was obtained from Cox-2 knockout mouse strains, which show severe defects in their kidneys [5, 6]. Further studies revealed a specific and tightly regulated pattern of gene expression in developing rats, mice, and humans [8–10]. The defects noted in the kidney included immature glomeruli, and the severity of RD in dogs is classified by the percentage of fetal glomeruli found on biopsy.
This study shows that novel allelic variants in the CpG island of the Cox-2 promoter have aberrant methylation of the Cox-2 promoter only in clinical cases of RD. The wild-type alleles are never methylated, even in animals that are heterozygous for a mutant allele. This in effect provides an internal control for methylation and shows a distinct resistance of the wild-type chromosome to methylation. This finding of methylation resistance was further reinforced by the lack of methylation in homozygous wild-type controls. These results provide strong evidence that the mechanism of action of the mutant alleles likely involves some degree of transcriptional downregulation via methylation of the CpG island in the Cox-2 promoter. Such a mechanism is supported by a previous study on cancer cell lines, in which methylation of the Cox-2 promoter resulted in decreased expression or silencing of the Cox-2 gene, depending on the extent of methylation [13, 14]. These findings are consistent in different types of cancer. The results of the present study also explain the mode of inheritance as dominant with incomplete penetrance because the degree of methylation varies between the clinical cases. The occurrence of aberrant methylation in different breeds and therefore in different genetic backgrounds reinforces the notion of a universal mechanism of action.
In general, Cox-2 is an inducible enzyme, but it has a basal level of expression in a subset of adult kidney tissues that is elevated in response to external stimuli, highlighting the complex regulation of this gene . In a previous study, RT-PCR showed Cox-2 expression in adult kidneys, although this expression could have been in response to the inflammation intrinsic to this disease, and the expression may be regulated by transcription factors other than tissue-specific or developmental transcription factors . Although Cox-2 is expressed in a limited number of fetal tissues, the only defects observed in Cox-2 knockout and knockdown mouse models are dysplastic kidneys, suggesting that downregulation of Cox-2 may be tissue-specific in the developing fetus [5–7]. Embryogenesis would therefore be the critical time to evaluate downregulation of Cox-2; however, observation during embryogenesis is not practical in dogs.
For the proposed mechanism of action to work, methylated DNA must be present in kidney tissues. However, methylated DNA was also found in cheek cells, indicating that the epigenetic event occurred early in development and in cells of both mesodermal and ectodermal origin. The methylation may thus have been caused by either environmental factors or other genes.
There has been intense speculation regarding the role of epigenetics in kidney disease, and this study represents the first example of DNA methylation of a CpG island that is likely to be involved in a developmental disease process. Other genetically inherited dominant diseases with incomplete penetrance may involve a similar mechanism.
polymerase chain reaction
reverse transcription PCR.
The author wishes to thank J Kassis for a careful review of the manuscript and for her suggestions for this article. The author also wishes to thank her co-authors from the original article published in PLos One for their continuing support of this research.
- Dressler GR: Epigenetics, development, and the kidney. J Am Soc Nephrol. 2008, 11: 2060-2070.View ArticleGoogle Scholar
- Smith WL, DeWitt DL, Garavito RM: CYCLOOXYGENASES: structural, cellular, and molecular biology. Annu Rev Biochem. 2000, 69: 145-182. 10.1146/annurev.biochem.69.1.145.View ArticlePubMedGoogle Scholar
- Harper KA, Tyson-Capper AJ: Complexity of COX-2 gene regulation. Biochem Soc Trans. 2008, 36: 543-545. 10.1042/BST0360543.View ArticlePubMedGoogle Scholar
- Okamoto T, Hino O: Expression of cyclooxygenase-1 and -2 mRNA in rat tissues: tissue-specific difference in the expression of the basal level of mRNA. Int J Mol Med. 2000, 4: 455-457.Google Scholar
- Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee D, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM, Gorry SA, Trzaskos JM: Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature. 1995, 23: 406-409.View ArticleGoogle Scholar
- Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA, Smithies O: Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell. 1995, 83: 473-482. 10.1016/0092-8674(95)90125-6.View ArticlePubMedGoogle Scholar
- Seta F, Chung AD, Turner PV, Mewburn JD, Yu Y, Funk CD: Renal and cardiovascular characterization of COX-2 knockdown mice. Am J Physiol Regul Integr Comp Physiol. 2004, 296: R1751-R1760.View ArticleGoogle Scholar
- Stanfield KM, Bell RR, Lisowski AR, English ML, Saldeen SS, Khan KN: Expression of cyclooxygenase-2 in embryonic and fetal tissues during organogenesis and late pregnancy. Birth Defects Res A Clin Mol Teratol. 2003, 67: 54-58. 10.1002/bdra.10032.View ArticlePubMedGoogle Scholar
- Kömhoff M, Wang JL, Cheng HF, Langenbach R, McKanna JA, Harris RC, Breyer MD: Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int. 2000, 57: 414-422.PubMedGoogle Scholar
- Kömhoff M, Grone HJ, Klein T, Seyberth HW, Nüsing RM: Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol. 1997, 272: F460-F468.PubMedGoogle Scholar
- Whiteley MH, Bell JS, Rothman DA: Novel allelic variants in the canine cyclooxgenase-2 (cox-2) promoter are associated with renal dysplasia in dogs. PLoS One. 2011, 6: e16684-10.1371/journal.pone.0016684.PubMed CentralView ArticlePubMedGoogle Scholar
- Li LC, Dahiya R: MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002, 18: 1427-1431. 10.1093/bioinformatics/18.11.1427.View ArticlePubMedGoogle Scholar
- Toyota M, Shen L, Ohe-Toyota M, Hamilton SR, Sinicrope FA, Issa JP: Aberrant methylation of the cyclooxygenase 2 CpG island in colorectal tumors. Cancer Res. 2000, 60: 4044-4048.PubMedGoogle Scholar
- Hur K, Song SH, Lee HS, Ho Kim W, Bang YJ, Yang HK: Aberrant methylation of the specific CpG island portion regulates cyclooxygenase-2 gene expression in human gastric carcinomas. Biochem Biophys Res Commun. 2003, 310: 844-851. 10.1016/j.bbrc.2003.09.095.View ArticlePubMedGoogle Scholar
- Herman JG, Myöhänen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996, 93: 9821-9826. 10.1073/pnas.93.18.9821.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.